Sugi Predict

Sugi Predict / Compounds / SCHEMBL6847369

SCHEMBL6847369

SCHEMBL6847369

CC1C(=O)N(NC[C@H](C)NC(=O)OC(C)(C)C)c2ccccc2-c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 7/20 0.39
▸ CCKAR P32238 3/20 0.39
▸ CCKBR P32239 3/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ MALT1 Q9UDY8 1/20 0.37
▸ PSEN1 P49768 2/20 0.36
▸ PSEN2 P49810 2/20 0.36
▸ APH1B Q8WW43 2/20 0.36
▸ NCSTN Q92542 2/20 0.36
▸ APH1A Q96BI3 2/20 0.36
▸ PSENEN Q9NZ42 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421108 0.83 PSEN1 (0.42) SCN9ACCKARCCKBRPSEN1PSEN2
SCHEMBL4417737 0.83 PSEN1 (0.42) SCN9ACCKARCCKBRPSEN1PSEN2
SCHEMBL6849588 0.82 PSEN1 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4418511 0.81 SCN9A (0.39) SCN9ACCKARCCKBRPSEN1PSEN2
SCHEMBL4424746 0.81 SCN9A (0.39) SCN9ACCKARCCKBRPSEN1PSEN2
SCHEMBL7568374 0.81 SCN9A (0.39) SCN9ACCKARCCKBRPSEN1PSEN2
SCHEMBL6309319 0.80 SCN9A (0.40) SCN9ACCKARCCKBRIDO1PSEN1
SCHEMBL4421000 0.80 SCN9A (0.40) SCN9ACCKARCCKBRIDO1PSEN1
SCHEMBL4988318 0.78 MALT1 (0.41) SCN9ACCKARCCKBRMALT1PSEN1
SCHEMBL8140471 0.78 CA2 (0.38) SCN9ACCKARCCKBRPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6774125-B2 TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. 2004-08-10 — — US disclosed
US-20030153550-A1 Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds AUDIA JAMES E (US) 2003-08-14 — — US disclosed
US-6509331-B1 Bicyclic amides such as 5-('-(2S-hydroxy-3-methylbutyrl)-2S-aminopropyl)amino-7-methyl-5,7-dihydro -6H-dibenz(b,d)azepin-6-one ELAN PHARMACEUTICALS, INC. 2003-01-21 — — US disclosed
EP-1089981-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS. Elan Pharmaceuticals, Inc. (US) 2001-04-11 — — EP disclosed
EP-1042298-A1 POLYCYCLIC ALPHA-AMINO-EPSILON-CAPROLACTAMS AND RELATED COMPOUNDS Elan Pharmaceuticals, Inc. (US) 2000-10-11 — — EP disclosed
WO-1999067220-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
WO-1999032453-A1 POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1999-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153550-A1 Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds APP, IAPP, BACE1 SCN9A 3125/4885CCKAR 741/4885CCKBR 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.